Analyst Reco. Evolent Health, Inc.

Stocks

EVH

US30050B1017

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 20:39:45 11/06/2026 +04			5-day change	1st Jan Change
4.525 ^USD	+1.23%		+3.54%	+13.38%

05-15	Citigroup Adjusts Price Target on Evolent Health to $5.50 From $4, Maintains Buy Rating	MT
05-08	Evolent Health, Inc., Q1 2026 Earnings Call, May 07, 2026

Analyst Reco.

05-15	Citigroup Adjusts Price Target on Evolent Health to $5.50 From $4, Maintains Buy Rating	MT
03-02	Oppenheimer Adjusts Evolent Health Price Target to $6 From $12, Maintains Outperform Rating	MT
02-26	UBS Adjusts Evolent Health Price Target to $5 From $10, Maintains Buy Rating	MT
02-26	Truist Cuts Price Target on Evolent Health to $6 From $10, Keeps Buy Rating	MT
02-25	RBC Capital Adjusts Evolent Health PT to $3 From $5, Maintains Sector Perform Rating	MT
02-25	KeyBanc Downgrades Evolent Health to Sector Weight From Overweight	MT
11-13	Stephens Upgrades Evolent Health Inc to Overweight From Equalweight, Price Target is $7	MT
11-13	BMO Capital Initiates Coverage on Evolent Health With Outperform Rating	MT
11-12	Oppenheimer Adjusts Price Target on Evolent Health Inc to $12 From $18, Maintains Outperform Rating	MT
11-11	UBS Adjusts Price Target on Evolent Health to $10 From $15, Maintains Buy Rating	MT
11-10	Truist Cuts Price Target on Evolent Health to $10 From $16, Keeps Buy Rating	MT
11-07	Evolent Health Inc appoints Mario Ramos as CFO effective January 1, 2026 - SEC filing	RE
08/08/25	Evolent Health misses Q2 revenue estimates	RE
09/05/25	UBS Adjusts Price Target on Evolent Health to $15 From $14, Maintains Buy Rating	MT
10/04/25	Truist Cuts Price Target on Evolent Health to $14 From $15, Keeps Buy Rating	MT
16/01/25	UBS Adjusts Price Target on Evolent Health to $14 From $27, Keeps Buy Rating	MT
14/01/25	RBC Cuts Price Target on Evolent Health to $17 From $20, Keeps Outperform Rating	MT
10/01/25	Needham Initiates Evolent Health at Buy With $15 Price Target	MT
18/11/24	Oppenheimer Adjusts Evolent Health Price Target to $28 From $34, Maintains Outperform Rating	MT
11/11/24	UBS Adjusts Evolent Health Price Target to $27 From $44, Maintains Buy Rating	MT
08/11/24	Oppenheimer Adjusts Evolent Health Price Target to $34 From $45, Maintains Outperform Rating	MT
08/11/24	RBC Capital Adjusts Evolent Health Price Target to $20 From $42, Maintains Outperform Rating	MT
08/11/24	Stephens Downgrades Evolent Health to Equalweight, Price Target is $16	MT
08/11/24	Truist Securities Cuts Price Target on Evolent Health to $24 From $33, Maintains Buy Rating	MT
11/10/24	KeyBanc Initiates Evolent Health at Overweight With $35 Price Target	MT